Bingwei Ye
Research Subjects
Bingwei Ye has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Han-Fei Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
52 shared publications - Jane Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
52 shared publications - Sunil Sudarshan
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA
52 shared publications - Gia-Buu Tran
Research Group in Pharmaceutical and Biomedical Sciences, Faculty of Pharmacy Ton Duc Thang University Ho Chi Minh City Vietnam
46 shared publications - Kebin Liu
Georgia Cancer Center, Augusta University, Augusta, Georgia, USA
46 shared publications - Mengling Liu
Institute of Neural Regeneration and Repair and Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, China
46 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes down-regulated by simvastatin
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes down-regulated by simvastatin
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
Go analysis of genes up-regulated by simvastatin
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
Go analysis of genes up-regulated by simvastatin
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
High-risk neuroblastoma exhibits transcriptional activation of the mevalonate pathway that produces cholesterol and nonsterol isoprenoids. A better understanding of how this metabolic reprogramming contributes to neuroblastoma development could help identify potential prevention and treatment strategies. Here, we report that both the cholesterol and nonsterol geranylgeranyl-pyrophosphate branches of the mevalonate pathway are critical to sustain neuroblastoma cell growth. Blocking the mevalonate pathway by simvastatin, a cholesterol-lowering drug, impeded neuroblastoma growth in neuroblastoma cell line xenograft, patient-derived xenograft (PDX), and TH-MYCN transgenic mouse models. Transcriptional profiling revealed that the mevalonate pathway was required to maintain the FOXM1-mediated transcriptional program that drives mitosis. High FOXM1 expression contributed to statin resistance and led to a therapeutic vulnerability to the combination of simvastatin and FOXM1 inhibition. Furthermore, caffeine synergized with simvastatin to inhibit the growth of neuroblastoma cells and PDX tumors by blocking statin-induced feedback activation of the mevalonate pathway. This function of caffeine depended on its activity as an adenosine receptor antagonist, and the A2A adenosine receptor antagonist istradefylline, an add-on drug for Parkinson's disease, could recapitulate the synergistic effect of caffeine with simvastatin. This study reveals that the FOXM1-mediated mitotic program is a molecular statin target in cancer and identifies classes of agents for maximizing the therapeutic efficacy of statins, with implications for treatment of high-risk neuroblastoma.Significance:Caffeine treatment and FOXM1 inhibition can both enhance the antitumor effect of statins by blocking the molecular and metabolic processes that confer statin resistance, indicating potential combination therapeutic strategies for neuroblastoma.See related commentary by Stouth et al., p. 2091
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
High-risk neuroblastoma exhibits transcriptional activation of the mevalonate pathway that produces cholesterol and nonsterol isoprenoids. A better understanding of how this metabolic reprogramming contributes to neuroblastoma development could help identify potential prevention and treatment strategies. Here, we report that both the cholesterol and nonsterol geranylgeranyl-pyrophosphate branches of the mevalonate pathway are critical to sustain neuroblastoma cell growth. Blocking the mevalonate pathway by simvastatin, a cholesterol-lowering drug, impeded neuroblastoma growth in neuroblastoma cell line xenograft, patient-derived xenograft (PDX), and TH-MYCN transgenic mouse models. Transcriptional profiling revealed that the mevalonate pathway was required to maintain the FOXM1-mediated transcriptional program that drives mitosis. High FOXM1 expression contributed to statin resistance and led to a therapeutic vulnerability to the combination of simvastatin and FOXM1 inhibition. Furthermore, caffeine synergized with simvastatin to inhibit the growth of neuroblastoma cells and PDX tumors by blocking statin-induced feedback activation of the mevalonate pathway. This function of caffeine depended on its activity as an adenosine receptor antagonist, and the A2A adenosine receptor antagonist istradefylline, an add-on drug for Parkinson's disease, could recapitulate the synergistic effect of caffeine with simvastatin. This study reveals that the FOXM1-mediated mitotic program is a molecular statin target in cancer and identifies classes of agents for maximizing the therapeutic efficacy of statins, with implications for treatment of high-risk neuroblastoma.Significance:Caffeine treatment and FOXM1 inhibition can both enhance the antitumor effect of statins by blocking the molecular and metabolic processes that confer statin resistance, indicating potential combination therapeutic strategies for neuroblastoma.See related commentary by Stouth et al., p. 2091
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.